| Dr Christian George Massier, MD | |
|
5700 Cooper Foster Park Rd W, Lorain, OH 44053-4140 | |
| (440) 204-7400 | |
| (440) 204-7401 |
| Full Name | Dr Christian George Massier |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 26 Years |
| Location | 5700 Cooper Foster Park Rd W, Lorain, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700080140 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 35.095006 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marymount Hospital | Garfield heights, OH | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| South Pointe Hospital | Warrensville heights, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".
Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.
InfoLogix, Inc., a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, today announced that NASDAQ has granted the Company's request for an exception to NASDAQ's stockholder approval requirements, in accordance with NASDAQ Listing Rule 5635(f).
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
› Verified 2 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".
Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.
InfoLogix, Inc., a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, today announced that NASDAQ has granted the Company's request for an exception to NASDAQ's stockholder approval requirements, in accordance with NASDAQ Listing Rule 5635(f).
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christian George Massier, MD 1669 Sperrys Forge Trl, Westlake, OH 44145-2017 Ph: (440) 617-9218 | Dr Christian George Massier, MD 5700 Cooper Foster Park Rd W, Lorain, OH 44053-4140 Ph: (440) 204-7400 |
News Archive
On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions".
Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.
InfoLogix, Inc., a leading technology provider of enterprise mobility solutions for the healthcare and commercial industries, today announced that NASDAQ has granted the Company's request for an exception to NASDAQ's stockholder approval requirements, in accordance with NASDAQ Listing Rule 5635(f).
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.
› Verified 2 days ago
Monica Isabella, MD Surgery Medicare: Medicare Enrolled Practice Location: 3600 Kolbe Rd, Lorain, OH 44053 Phone: 440-960-4522 Fax: 440-960-4523 | |
Beverly J Paige, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 3600 Kolbe Rd, Ste 203, Lorain, OH 44053 Phone: 440-960-4522 Fax: 440-960-4523 | |
Fremio Vargas, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 221 W 21st St, Ste 5, Lorain, OH 44052 Phone: 440-245-4470 Fax: 440-245-1477 | |
Dr. Jeffrey Thomas Landers, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3600 Kolbe Rd Ste 206, Lorain, OH 44053 Phone: 440-222-4180 Fax: 440-222-4181 | |
Dr. Ching-feng Lai, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 5700 Cooper Foster Park Rd W, Lorain, OH 44053 Phone: 404-204-7439 Fax: 404-204-7584 | |
James J Andrasko, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3600 Kolbe Rd, Suite 203, Lorain, OH 44053 Phone: 440-960-4522 Fax: 440-960-4523 |